Menu
Live News EQUITY H impact

RGNX Aligns with FDA

REGENXBIO announces alignment with FDA on path forward for NAVSUNLI BLA resubmission for accelerated approval

RGNX

RGNX - REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II